CagriSema

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ObesityDiabetes Mellitus, Type 2

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Maridebart Cafraglutide

Amgen

Phase 3

72

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

13

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

14

Eloralintide

Eli Lilly

Phase 3

105

Elecoglipron

AstraZeneca

Phase 3

16

Belantamab Mafodotin-Blmf

Novo Nordisk

Phase 3

17

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

18

CagriSema

Novo Nordisk

Phase 3

59

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

110

Avapro

Sanofi

Preclinical

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity5 trials

The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study

Active, not recruiting·Novo Nordisk·Phase 1·NCT07184086·80 enrolled

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

Recruiting·Novo Nordisk·Phase 3·NCT07564414·2,500 enrolled

Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity

Completed·Novo Nordisk·Phase 1·NCT06716307·18 enrolled

Show 2 more trials

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Active, not recruiting·Novo Nordisk·Phase 3·NCT07011667·609 enrolled

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

Withdrawn·Novo Nordisk·Phase 3·NCT07357766

Diabetes Mellitus, Type 24 trials

Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

Not yet recruiting·Novo Nordisk·Phase 3·NCT07817251·210 enrolled

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Completed·Novo Nordisk·Phase 2·NCT06797869·142 enrolled

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

Recruiting·Novo Nordisk·Phase 3·NCT07282613·80 enrolled

Show 1 more trial

A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

Withdrawn·Novo Nordisk·Phase 2·NCT07357740

Details

Drug Info

Related News